China SXT files Form 3 for Co-CEO Lim

China SXT Pharmaceuticals, Inc. filed an initial ownership report (Form 3) for Simon Lim Sze Beng, who serves as Co-Chief Executive Officer.

Rhea-AI Filing Summary

China SXT Pharmaceuticals, Inc. filed an initial ownership report (Form 3) for Simon Lim Sze Beng, who serves as Co-Chief Executive Officer. This filing lists him as an officer but shows no reported share transactions, derivative positions, or current holdings in the data provided.

Key Terms

Form 3, Co-Chief Executive Officer, insider ownership

3 terms

Form 3 regulatory

"China SXT Pharmaceuticals, Inc. filed an initial ownership report (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Co-Chief Executive Officer financial

"Simon Lim Sze Beng, who serves as Co-Chief Executive Officer"

insider ownership financial

"filed an initial ownership report (Form 3) for Simon Lim Sze Beng"

The percentage of a company’s stock held by people with access to inside information or control, typically officers, directors and large shareholders who work at or help run the business. It matters to investors because it shows how much “skin in the game” insiders have and can signal alignment of interests, potential for concentrated control, and effects on share liquidity—like neighbors owning most of a street, which changes how decisions are made and how easy it is for others to move in or out.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SXTC Form 3 filing for Simon Lim Sze Beng show?

The Form 3 identifies Simon Lim Sze Beng as Co-Chief Executive Officer of China SXT Pharmaceuticals. In the provided data, it reports no buy or sell transactions, no derivative activities, and no holding entries or positions.

Does the SXTC Form 3 indicate any share purchases or sales by Simon Lim Sze Beng?

No. The transaction summary for Simon Lim Sze Beng shows zero buy and sell counts, zero net shares bought or sold, and no derivative transactions, indicating no reported trading activity in this Form 3 data excerpt.

What insider role is disclosed for Simon Lim Sze Beng at China SXT Pharmaceuticals (SXTC)?

The filing lists Simon Lim Sze Beng as an officer of China SXT Pharmaceuticals with the title Co-Chief Executive Officer. He is not flagged as a director or a ten percent owner in the structured data provided.

Are there any derivative securities reported for Simon Lim Sze Beng in this SXTC Form 3?

No. The derivative summary is empty and derivativeTransactionCount is zero, indicating no reported options, warrants, or other derivative positions for Simon Lim Sze Beng in this particular Form 3 dataset.

Does the SXTC Form 3 for Simon Lim Sze Beng include any gifts or tax-withholding transactions?

No. The transaction summary shows giftCount and taxWithholdingCount as zero, with corresponding share values also at zero, indicating no gifts or tax-withholding share dispositions in this Form 3 excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Simon Lim Sze Beng

(Last) (First) (Middle)

41, JALAN WIRAWATI 3, MALURI, 55100

(Street)

KUALA LUMPUR WILAYAH PERSEKUTUAN

(City) (State) (Zip)

MALAYSIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
01/20/2025

3. Issuer Name and Ticker or Trading Symbol
China SXT Pharmaceuticals, Inc. [ SXTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Simon Lim Sze Beng	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)